/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead.
Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer remains on track with interim data anticipated in mid-2024
Closed a $200 million oversubscribed private.
As the year comes to an end, biopharma and life sciences companies are strengthening their leadership teams and boards with the latest round of Movers & Shakers.
Former FDA head Stephen Hahn is adding a new title to his role at Flagship Pioneering: CEO of the incubator's blood cancer test startup Harbinger Health. Takeda's oncology leader Rachael Brake heads to Corbus as chief scientific officer charged with redefining scope of early-stage pipeline. Goldfinch Bio snags 13-year Ardelyx vet as CSO.